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Objective. Raynaud's phenomenon (RP) is common in anti-RNP-positive patients with rheumatic diseases but is not itself known to be caused by autoimmunity. The aim of this study was to assess autoantibodies that could mediate this process.
Methods. Antibodies derived from patient sera and from murine models of anti-RNP autoimmunity were screened for the ability to induce RP-like tissue ischemia and endothelial cell apoptosis in murine models and in vitro systems.
Results. RNP-positive sera from RP patients and murine sera from RNP-positive B cell adoptive transfer recipients induced RP-like tissue ischemia and endothelial cell apoptosis. Proteomic analysis identified cytokeratin 10 (K10) as a candidate autoantigen in RP. Monoclonal anti-K10 antibodies reproduced patterns of ischemic tissue loss and endothelial cell apoptosis; K10 knockout or depletion of anti-K10 activity in serum was protective. Cold exposure enhanced K10 expression and in vivo tissue loss.
Conclusion. Anti-K10 antibodies are sufficient to mediate RP-like ischemia in murine models and are implicated in the pathogenesis of RP in patients with anti-RNP autoimmunity.
There are 2 forms of Raynaud's phenomenon (RP; cold-induced peripheral vasospasm). The first form, primary (benign) RP, occurs in 10% of healthy young women and is associated with minimal morbidity (1) . The second form, autoimmunity-associated RP, is common in systemic sclerosis (scleroderma) and related autoimmune rheumatic diseases in which anti-RNP antibodies are present (2) and can be associated with significant morbidity, including gangrene and tissue loss in the fingers and toes (3) . Current therapy for autoimmunity-associated RP includes use of vasodilator drugs to reduce local manifestations of ischemia (4) but does not address the underlying pathogenesis of the process. Studies of RP pathogenesis have identified abnormalities in vascular tone and response to neuroendocrine stimuli (5) but have struggled to connect RP to autoimmunity.
Endothelial cell apoptosis has been regarded as a central event in the pathogenesis of scleroderma and has the potential to drive both vasospastic and fibrotic disease manifestations (6) . Sera from scleroderma patients have previously been shown to induce apoptosis of cultured endothelial cells (7, 8 ). An avian model of spontaneous RP has been described, in which increased apoptosis of endothelial cells in the area of vasospasm can be observed and in which serum from affected birds also induces endothelial cell apoptosis (9, 10) . A pathway by which scleroderma antisera could induce apoptosis of endothelial progenitor cells has been identified, in which seruminduced inhibition of Akt signaling leads to up-regulation of Bim expression and hence apoptosis, but the target antigen/receptor has not been defined (11) . In the current study, we address the specificity of antisera that mediate endothelial cell apoptosis and connect this process with novel in vivo animal models.
Ear and tail vessels in mice have a thermoregulatory function similar to that of finger and toe vessels in humans, respond in a manner similar to the response in human digital arteries upon exposure to vasoconstrictors implicated in episodes of RP (12) , and would be the presumed targets of RP in mice. In contrast, murine digits have not been observed to share the thermoregulatory function seen in human digits. Our group previously developed an induced murine model of anti-RNP autoimmunity with lung and renal manifestations consistent with human mixed connective tissue disease (MCTD) (13, 14) . However, RP manifestations do not develop in this murine model, although >90% of MCTD patients were found to have this manifestation (15) .
Case reports of improvement after anti-B cell therapy in RP patients with anti-RNP autoimmunity have been published (16, 17) . Some anti-RNP antibodies have been shown to bind endothelium, which supports a link between humoral autoimmunity and RP (18) . We therefore hypothesized that a previously uncharacterized set of autoantibodies that induce endothelial cell apoptosis could be pathogenic for RP, and that high titers of these antibodies develop in patients with RP.
Although we previously reported immunologically distinct anti-RNP responses in patients with RP (2), a specific target antigen that is expressed on endothelium, that induces endothelial cell apoptosis when bound by a cognate antibody, and that can induce RP-like ischemia of thermoregulatory tissue has not previously been described.
In this report. we describe murine models of RPlike ischemic lesions that can be induced by transfer of B cells, transfer of murine serum, transfer of RP patient serum, or transfer of monoclonal antibodies (mAb) to the novel autoantigen cytokeratin 10 (K10). The study results show that anti-K10 antibodies can be found in RP patient sera, that anti-K10 antibodies can induce endothelial cell apoptosis in vitro, and that anti-K10-mediated apoptosis and tissue loss are prevented in K10-knockout mice. We also show that Bim-knockout mice are resistant to antibody-induced tissue ischemia. Collectively, these results establish novel murine models of RP, demonstrate that RP can be an autoimmune process mediated through anti-intermediate filament antibodies, and indicate that the cytokeratin 10 antibody/antigen system (and its downstream signaling pathway) may be relevant targets for novel diagnostic and therapeutic approaches in RP.
PATIENTS AND METHODS
Study approval. All human samples and data were collected and used according to institutional review board (IRB)-approved protocols. Patients and normal control subjects were recruited and provided written informed consent for study participation according to IRB-approved protocols. All animal studies were performed according to Institutional Animal Care and Use Committee (IACUC)-approved protocols in Association for Assessment and Accreditation of Laboratory Animal Careapproved facilities, in adherence with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Experimental design. The primary study design consisted of controlled laboratory experiments. Predefined outcomes included the frequency and extent of local tissue ischemia in the ears and tails of study mice and the extent of apoptosis induction as measured by caspase 3/7 activation using a commercial colorimetric indicator. Power analyses based on preliminary data were performed prior to each experiment. Studies had 80% power to detect a significant difference at an alpha level of 0.05 or less. Tissue ischemia in the study mice was evaluated by trained study personnel who were blinded with regard to the treatment arm(s). Studies with human sera were performed using a sample of clinically characterized RNP-positive patients recruited for study at our center for whom antisera were available, and a cohort of healthy subjects (19) .
Human and animal studies. Patients who were seen at our center between 2006 and 2015 were characterized as being RNP-positive if they had a positive result of a clinical laboratory anti-RNP test and/or if anti-RNP antibodies were identified in our laboratory by enzyme-linked immunosorbent assay (ELISA) or immunoblotting (19, 20) . Subject data were obtained by structured interview, physical examination, laboratory screening, and review of medical records (15) . A diagnosis of RP was designated in patients who reported a history of cold-induced color changes in the digits following the validated picture-question format (questionnaire combined with color charts) described by Maricq and Weinrich (21) . Serum samples obtained from the study subjects at the time of a research encounter were kept in frozen aliquots at À80°C.
C57BL/6 mice were obtained from The Jackson Laboratory except as indicated below. HLA-DR4-transgenic mice on a B6 background, as previously described, were obtained from Taconic (13) . To induce anti-RNP autoimmunity, female 8-10-week-old mice were immunized subcutaneously, as previously described (13, 14) , with 50 lg each of 70K (as a maltose binding protein fusion protein) and U1 RNA together in 50 ll of sterile phosphate buffered saline (PBS). Successful immunizations were confirmed by a 70K ELISA, as previously described (19, 20) . K10-knockout mice and control BALB/c mice (the background strain on which the K10 knockout was produced) were obtained from Thomas M. Magin (22) , confirmed to be genetically homozygous for the K10-knockout genotype by sequencing of tail clip samples (Transnetyx), and established by immunohistochemical analysis and immunoblotting to have undetectable levels of K10 protein in endothelial cells. Bim-knockout mice were generated by crossing Bim fl/fl mice on a C57BL/6 (B6) background with a ROSA26-cre mouse, resulting in a germline deletion of the floxed allele of Bim (23, 24) . Mice were crossed until homozygous deleted mice were obtained. Inbred littermate B6 mice were used as controls.
In vivo cold exposure experiments in mice were performed under isoflurane-inhaled anesthesia, according to IACUC-approved protocols. Specific body parts (1 ear) were exposed to a 4°C thermal pad for 1 minute and then returned to usual body temperature under warming pad conditions.
Cell culture. All cell culture experiments were performed in accordance with Institutional Biosafety Committeeapproved protocols. Human umbilical vein endothelial cells (HUVECs) (Lonza) were maintained in Endothelial Cell Growth Medium (Lonza; catalog no. 3024A). Short-term murine endothelial progenitor cell cultures were developed from the bone marrow of B6, BALB/c, or K10-knockout mice, according to the protocol described by Zhu et al (25) . Studies were performed in HUVECs and endothelial progenitor cells after undergoing <8 passages.
Cold exposure studies were performed in vitro by placing the cells in medium cooled to 4°C for the indicated time points (typically 1 minute for cold pre-exposure) before replacing the cooled medium with 37°C medium. Bacterial transfection and culture to express and purify K10 proteins were performed as previously described (20, 26) . Plasmids expressing K10-MBP and hexahistidine-tagged K10 were obtained from Thomas M. Magin and Jose L. Jorcano, respectively. Protein was purified from sonicated cell lysate by column chromatography (amylose or nickel columns) and, following gel purification, was validated by tandem mass spectrometry and immunoblotting.
B cell and antibody adoptive transfer studies. Single-cell suspensions from the spleens of immunized and control mice were prepared as previously described (14, 26) . B cells were purified using an autoMACS B cell separation kit, and the purity of B cell markers, as determined by fluorescence-activated cell sorting, was consistently >90%. Adoptive transfers were performed with 5 9 10 5 cells in 400 ll of sterile PBS, injected into the tail veins of 10-12-week-old naive syngeneic mice with a sterile 26-gauge needle, as described in previous T cell and dendritic cell transfer studies (14, 26) . Serum (up to 50 ll) and commercial antibody (up to 50 lg in 50 ll) transfer studies were similarly performed by a single tail vein injection into 10-12-week-old recipient mice. Recipient mice were followed up for 2 weeks prior to being killed. At the time when the mice were killed, serum was collected, and tissue samples were processed for histologic evaluation (14, 26) .
Anti-K10 mAb included clone LH2, a murine IgG1 mAb raised against human K10 with reported reactivity against both human and mouse cytokeratin 10 (LifeSpan BioSciences); clone VIK-10, a murine monoclonal IgG1 antibody with anti-K10 specificity raised against a human epidermal cytoskeletal extract (Thermo Fisher Scientific); and clone AE20, a murine monoclonal IgG antibody specific for human K10 (GenWay Biotech). Isotype controls included clone AE1, a mouse IgG1 monoclonal antibody raised against human epidermis with reported activity against both human and murine acidic cytokeratins prominently, including cytokeratin 9 (Genway Biotech). Conjugations of antibodies to fluorescent markers were performed by the commercial suppliers. For indirect immunofluorescence testing using human sera, fluorescein isothiocyanate (FITC)-conjugated goat anti-human IgG was used at a 1:500 dilution. Anti-K10 ELISAs were performed in a manner similar to those used for the anti-70K ELISAs. For the IgG ELISAs, K10/MBP was used to coat the plate wells, and purified MBP was used to coat wells in parallel to define background staining. For the IgM ELISAs, hexahistidinetagged K10 was used to coat wells in the same buffer and at the same concentration and compared with wells incubated in blocking buffer to define background staining. Horseradish peroxidase-labeled goat anti-human IgM (Southern Biotech) (1:5,000 dilution) was used as the second antibody for the IgM ELISAs.
Immunoprecipitation and protein identification. The reverse immunophenotyping approach previously described by our group was used to identify the 56-kd band induced in endothelial cells and recognized in endothelial cell lysates by RP patient sera but not control sera (27) . Briefly, serum samples from representative anti-RNP-positive patients with RP versus patients without RP were bound to protein A-Sepharose beads. HUVECs were lysed in sample buffer and used as the antigen sources. Lysates were either used unmodified or pre-cleared with the RP-positive or RP-negative anti-RNP sera. Antibody-conjugated beads and lysates were allowed to coincubate overnight at 4°C and then spun and washed in immunoprecipitation buffer, suspended in sample buffer, and electrophoresed on a standardsize 10% polyacrylamide gel, and bands were visualized by Coomassie staining. The candidate 56-kd band preferentially immunoprecipitated by sera from patients with RP was excised, digested with trypsin in situ, eluted, and subjected to tandem matrix-assisted laser desorption ionization-time-of-flight mass spectrometry for sequence analysis of derivative peptides. Use of the Sequest search engine and Proteome Discoverer software generated probability scores for the identity of electrophoretically separated parent proteins.
Histopathologic analysis. Conventional sections from murine tissue samples were fixed in UMFix (Sakura Finetek USA) and stained with hematoxylin and eosin, as previously described (13, 14) . In vivo TUNEL staining was performed on mice that had been previously exposed to 50 ml of human RNPpositive/RP-positive sera or normal control human sera, by in vivo labeling using an ApopTag Plus Peroxidase Kit (EMD Millipore) and killing the mice 32 hours later. Caspase 3/7 staining was performed in vitro with CellEvent Caspase-3/7 Green Detection Reagent (Thermo Fisher Scientific) according to the instructions of the manufacturer. For the caspase assays, fluorescent images of intact unpermeabilized cells were captured using an Olympus (1X71) inverted fluorescence microscope.
Statistical analysis. Groups were compared by Fisher's exact test for categorical data and t-tests for quantitative data, using Prism 5.0 and GraphPad QuickCalcs. Odds ratios were calculated using MedCalc software.
RESULTS
Murine models of anti-RNP thermoregulatory tissue ischemia. We previously observed distinct clinical phenotypes associated with adoptive transfer of specific subsets of spleen cells (T cells or dendritic cell subsets) from RNP-immunized mice into syngeneic controls (14) . We performed similar studies to assess whether splenic B cell adoptive transfer would similarly induce a particular phenotype. We observed that adoptive transfer of splenic B cells from RNP-immunized HLA-DR4-transgenic B6 mice, but not from naive syngeneic B cell donors, induced ear and tail ischemia and tissue loss within 2 weeks of cell transfer in mice housed under standard conditions (Figure 1) , with ischemic lesions evident in 14 (82%) of 17 recipients of B cells from RNPpositive donors versus 0 of 5 recipients of naive splenic B cells (P = 0.002 by Fisher's exact test). Among >500 HLA-DR4-transgenic B6 mice directly immunized to develop anti-RNP antibodies in our ongoing and prior studies, no other cases of spontaneous ear or tail gangrene and tissue loss were observed.
Sera from the RNP-positive B cell recipients that developed ear and tail ischemia also induced ear and tail ischemia within 2 weeks of intravenous infusion into naive syngeneic mice (housed under standard conditions), in a dose-dependent manner (Figure 2A ). Similar ischemic lesions were not observed with serum transfer from either naive mice (data not shown) or RNP-immunized mice that served as B cell donors.
We performed similar serum transfers into naive mice of the same strain using serum from a patient with MCTD, anti-RNP autoimmunity, and a history of active RP. This patient's serum likewise induced progressive ear ischemia and tissue loss within 2 weeks ( Figure 2B ). No effects were observed with transfer of control serum.
Histologic analysis of RP patient serum recipients 2 weeks after transfer revealed no significant internal organ derangements and no evidence of vasculitis or thrombosis (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40505/abstract). Increased apoptosis as shown by TUNEL staining was observed in the ear and tail vasculature of mice receiving ischemia-inducing sera ( Figure 2C) .
Identification of K10 as a target autoantigen and association of anti-K10 antibodies with RP-like ischemia. Ischemia-inducing anti-RNP-positive serum from a patient with RP but not control human anti-RNP-positive serum from a subject without RP showed anti-endothelial cell Immunoprecipitation of HUVECs using serum from the MCTD patient with RP (as shown in Figure 2 ) that induced murine ischemia identified a 56-kd band that was not present in RNP-positive serum from a subject without RP that did not induce ischemia in mice after serum transfer ( Figure 3B ). Mass spectroscopy analyses identified the immunoprecipitated 56-kd band as K10. Although previous studies of K10 expression have primarily used skin cells, we observed that endothelial cells do express K10 messenger RNA (mRNA) and protein ( Figures 3C and D) . In contrast to the expression of other endothelial cell cytokeratins, endothelial cell K10 expression levels were substantially up-regulated at the mRNA and protein levels by brief exposure of endothelial cell cultures to cold temperature. Similar changes in expression were also evident by immunofluorescence with directly FITC-conjugated anti-K10 (see Supplementary  Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40505/ abstract).
To test whether anti-K10 antibodies were sufficient to induce ischemic lesions, we performed intravenous treatment of the HLA-DR4-transgenic B6 mice with commercially available anti-K10 mAb. Anti-K10 mAb with established reactivity against murine K10 (both the Figure 2 . Serum transfer of ischemia phenotype. A, Murine serum transfer from ischemic B cell recipients (as described in Figure 1 ) induced dose-dependent tissue loss by day 14 (arrows), which was not seen with serum transfer from B cell donors. B, Transfer of serum from a patient with Raynaud's phenomenon (RP), following the same protocol as that described in A, induced progressive ear tissue loss (arrows) from day 0 to day 6 to day 15 in the same mouse, which was not observed in a mouse treated with serum from a healthy control subject. C, Transfer of RP patient serum induced vascular apoptosis. Two weeks after mice received RP patient serum or healthy control serum, ear tissue showed increased TUNEL staining (brown) in the recipient of RP patient serum compared with that in the recipient of normal control serum. Staining was most prominent near the lumens of blood vessels (arrows). Original magnification 9 10.
LH2 and VIK-10 antibodies) induced ischemic ear lesions similar to those seen with the murine and human sera (Figure 4) .
We sought to further investigate the hypothesis that anti-K10 antibodies in RP patient sera induce endothelial cell apoptosis. We assessed in vitro activation of endothelial cell caspase 3/7 after 24-hour serum incubations using anti-RNP-positive patient sera and sera from healthy control subjects. The presence of anti-K10 IgG antibodies as determined by ELISA in RNP-positive patients was correlated with induction of a high level of caspase signaling, both in patients with clinical RP and in subjects in whom clinical RP had not been appreciated, compared with RNP-positive patients without anti-K10 antibodies (either with or without RP) and compared with control sera from healthy subjects ( Figure 5A ). All 11 of the RNP-positive/K10-positive sera tested showed high levels of in vitro endothelial cell caspase activation (defined as 2 SD above the mean caspase activation by control sera), as did 3 of 6 of the sera in the RNP-positive/K10-negative/RP-positive group (P = 0.029 versus anti-K10-positive sera, by Fisher's exact test), 0 of 6 of the sera in the RNP-positive/K10-negative/RP-negative group (P < 0.0001 versus RNP-positive/K10-positive sera, by Fisher's exact test), and 0 of 11 of the K10-negative healthy control sera (P < 0.0001 versus RNP-positive/K10-positive sera and P = 0.036 versus the RNP-positive/K10-negative/RP-positive sera, by Fisher's exact test). Differences in caspase activation were reflected by Although low levels of K10 protein were present in HUVECs at 37°C, the quantity of protein was dramatically increased in cold-exposed cells (compared with GAPDH loading control). ND = not determined. Figure 5 . K10-dependent endothelial cell apoptosis. A, Caspase 3/7 activity assessed using sera from RNP-positive/K10-positive and RNP-positive/ K10-negative RP patients, RNP-positive/K10-positive and RNP-positive/K10-negative sera from patients without RP, and sera from healthy control subjects. Results are representative of 3 independent experiments. Bars show the mean AE SD. ** = P < 0.041 versus K10-negative RP patient sera, P < 0.003 versus K10-negative sera from patients without RP, and P ≤ 0.0001 versus control K10-negative sera, by t-test. * = P < 0.048 versus K10-negative sera from patients without RP, and P < 0.009 versus K10-negative control sera, by t-test. B, Caspase 3/7 activity in endothelial cells from BALB/c and K10-knockout mice exposed to increasing dilutions of control sera or RNP-positive/K10-positive sera from patients with RP for 24 hours. Values are the mean AE SD and are representative of 2 independent experiments. See Figure 3 for other definitions. . K10-knockout cells, anti-K10 depletion, or Bim-knockout cells prevent ischemia. Twenty-four hours before antibody injections were administered, 1 ear of each mouse was exposed to a temperature of 4°C for 1 minute. Ear length was measured at baseline and on day 14. A, Ear length in BALB/c and K10-knockout mice exposed to cold medium (4°C) and warmed medium (37°C). In 4 of 5 BALB/c mice, ear loss was observed only after exposure to cold. No ear loss was observed in K10-knockout mice, regardless of cold exposure. Bars show the mean AE SD. * = P = 0.008 versus K10-knockout mice, by t-test. B, Effect of depletion and mock depletion of anti-K10 from RNP-positive/K10-positive RP patient serum. Serum was depleted by incubation with his 6 -K10-loaded nickel-Sepharose beads or was mock-depleted. Caspase 3/7 activation was measured in HUVECs treated with control, depleted, and mock-depleted sera, as described in Figure 5 . The caspase-inducing activity of RP-positive serum was minimally affected by mock depletion but was reduced to nearly the level of healthy control serum with K10 depletion. Values are the mean AE SD. C, Ear length on day 0 and day 14 in B6 mice receiving serum with or without anti-K10 depletion on day 0. Results are shown for mouse ears exposed to cold prior to serum transfer (see Methods) and for contralateral ears of the same mice that were not cold-exposed (warm). Bars show the mean AE SD.* = P = 0.008 by Fisher's exact test. D, Ear length in Bim-knockout and germline control B6 mice on day 0 and day 14 after administration of anti-K10-positive human serum; only cold-exposed ears are shown. Squares represent mice in which ear loss was observed; circles represent mice with no ear loss. Bim-knockout mice were protected against ear loss, but Bim-intact mice were not. Values are the mean AE SD. * = P = 0.033 versus day 0, by Fisher's exact test. mAb = monoclonal antibody (see Figure 3 for other definitions). differences in cell death according to morphology criteria in HUVECs (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40505/abstract).
Among a larger number of well-characterized RNP-positive patients at our center, ELISA screening showed that anti-K10 antibodies (either IgG or IgM) were detectable in 48% of patients (56 of 116) (see Supplementary Table 1, available Table 2 ).
To further investigate the role of K10 in humorally mediated induction of endothelial cell apoptosis, we tested endothelial cell cultures from K10-knockout mice versus their background strain (BALB/c) for responsiveness to different dilutions of human sera at 37°C (Figure 5B ). As expected, we observed that caspase 3/7 was highly activated in K10-intact endothelium when exposed to increasing concentrations of RNP-positive serum from a patient with RP whose serum had been shown by ELISA to have high-titer anti-K10 IgG and IgM antibodies and to induce clinical ear and tail ischemia when transferred into study mice. Much less caspase activation was observed with increasing concentrations of a normal control human serum. Caspase activation induced by human sera was substantially attenuated in endothelial cells from K10-knockout mice compared with endothelial cells from K10-intact mice.
Despite exposure to the same doses of anti-K10-positive RP patient sera used in B6/HLA-DR4-transgenic mice, germline K10-expressing BALB/c mice developed ischemic lesions less frequently than the B6/HLA-DR4-transgenic mice, with none of 5 mice showing ear lesions other than subtle ruffling of the ear edge and only 1 case of unequivocal tail ischemia among 5 treated BALB/c mice (see Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/d oi/10.1002/art.40505/abstract). To increase the expression of disease in the BALB/c mice, we used targeted cold exposure with the intention of up-regulating local K10 expression (as shown in Figure 3 ). When we pretreated 1 ear of each BALB/c mice with exposure to a temperature of 4°C for 1 minute 48 hours and again 24 hours before infusing the mice with anti-K10-positive patient sera, we could identify definite ear tissue loss-only on the coldpretreated side-in 4 of 5 mice (P = 0.047 by Fisher's exact test) ( Figure 6A ). Age-and sex-matched K10-knockout and BALB/c mice were concurrently treated with cold exposure prior to administration of the same dose of anti-K10-positive patient sera. The K10-knockout mice showed no ear or tail ischemic tissue loss. Indeed, when we measured the ear lengths of the germline BALB/c mice versus the K10-knockout mice starting at 10 weeks of age, we observed that the K10-knockout mice showed increases in the interval between the time of the initial measurement and the time of the final measurement in ear length that were not affected by the presence or absence of cold exposure or anti-K10 antibodies, whereas the BALB/c mice showed unchanged ear size with anti-K10 antibodies in the absence of cold exposure and clear tissue loss with the combination of cold pre-exposure and anti-K10 antibodies.
To further establish that anti-K10 antibodies mediated the ischemia-inducing effects of RP patient sera on the study mice, we depleted anti-K10 from a serum sample from an anti-RNP-positive/anti-K10-positive RP patient, using Sepharose beads bound to his 6 -K10 and transferred depleted or mock-depleted serum to BALB/c and K10-knockout study mice, as described above ( Figures 6B and  C) . Depletion of anti-K10 attenuated the induction of caspase 3/7 activity in HUVECs in vitro and prevented the development of ischemic lesions in the ears of study mice, whether or not the ears received cold pre-exposure (although cold pre-exposure exacerbated tissue loss with mock-depleted serum). Collectively, these observations provide further evidence of the role of K10 in mediating cold-associated ischemic tissue loss induced by RP patient sera.
Relevance of Bim in RP patient serum-induced ischemia. An RP-associated pathway of serum-induced endothelial progenitor cell apoptosis mediated through Akt inhibition and subsequent up-regulation of Bim was previously identified by Zhu and colleagues (11) . We therefore assessed whether Bim-knockout mice would be protected against anti-K10-induced tissue loss (Figure 6D) . We observed that Bim-knockout mice were protected against anti-K10-induced ischemic tissue changes (after cold pre-exposure) compared with the background Bim-intact B6 strain.
DISCUSSION
The results of this study link RP to an autoimmune response to a specific autoantigen, cytokeratin 10. The study demonstrates that direct serum transfer of anti-K10 antibodies is sufficient to induce RP-like ischemia in mice, shows that K10-knockout mice are protected against the development of ischemic tissue loss, and demonstrates in studies of anti-K10 depletion that other antibodies providing redundant ischemia-inducing activity need not be present in anti-RNP sera.
Previous studies of RP-associated serum-induced endothelial progenitor cell apoptosis have implicated Akt inactivation-induced Bim up-regulation in the pathogenic pathway (11) . In keratinocytes, K10 overexpression has been shown to lead to K10 aggregates that sequester and inactivate Akt (28) . The findings in our studies that higher titers of anti-K10 antibodies may be more strongly linked to RP manifestations support the notion that anti-K10 antibodies may be inducing the formation of similar K10 aggregates that mediate endothelial cell apoptosis. Our findings of the Bim dependence of serum-induced tissue ischemia in our murine model ( Figure 6 ) are consistent with this mechanism of action.
Our observations that cold exposure enhances endothelial cell K10 expression ( Figure 5 ) may help explain the predilection of RP for cold-exposed areas and may also help account for the reported seasonal variation in the rates of RP flares. The mechanism for RP induction (and cold sensing) that we propose is dependent on anti-K10 antibodies and K10-expressing endothelial cells, without a requirement for neurologic signals. However, this hypothesis does not exclude roles that neurologic signals may have in RP. Rather, it identifies new pathways in order to understand the mechanisms of neurologic effects on RP. For example, nerve signals could potentially alter the set point for induction of endothelial cell apoptosis (e.g., by changing expression levels of K10, Bim, or other modulators of endothelial cell apoptosis). Alternatively, nerve signals could influence manifestations of RP downstream of the induction of endothelial cell apoptosis (e.g., by influencing the extent/intensity of local vasospasm induced by an area of endothelial cell apoptosis).
Limitations of this study include disease-restricted (anti-RNP autoimmunity) assessment of the relationship between anti-K10 antibodies and RP. Further study of patients with other forms of RP-associated autoimmunity (such as subtypes of scleroderma with different clinical and autoantibody profiles) is needed to assess how general the association of anti-K10 with autoimmune RP may be.
Our results show that anti-K10 antibodies (even those demonstrated to induce endothelial cell death) can be observed in RNP-positive subjects who either do or do not have clinical RP. As shown in Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40505/abstract), anti-K10 positivity was barely observed in the majority of RP patients in our cohort and was observed in almost as large a percentage of subjects without RP as in patients with RP. Although it is possible that some subjects in whom anti-K10 antibodies were present at high titers but RP had not been appreciated clinically may develop RP in the future, our animal studies suggest that high-titer anti-K10 antibodies are not the only factor that determines whether or not clinical RP will emerge.
Although the presence of anti-K10 antibodies often led to profound tissue loss in B6 mice in our studies, high levels of anti-K10 antibodies in germline BALB/c mice typically led to only subtle (if at all noticeable) clinical changes, unless the endothelial cell apoptosis pathway activated by anti-K10 antibodies was primed (such as by prior cold induction of endothelial cell K10 expression). Compared with B6 mice, BALB/c mice express lower levels of K10; sufficient levels of K10 expression are likely required for clinical expression of anti-K10-induced RP. Our K10 depletion studies in vitro suggest that anti-RNPpositive sera, even in the absence of interactions between anti-K10 and K10, can induce at least some level of endothelial cell apoptosis and may therefore potentiate the effects of anti-K10. Antibodies to such non-K10 specificities could also be associated with anti-K10-negative cases of RP. In our experiments ( Figure 5 ), it was not unusual for sera from RNP-positive patients with RP but with negative ELISA results for anti-K10 to still show caspase-activating effects. Further studies will be needed to assess whether anti-K10-positive RP patients have a worse prognosis regarding ischemic complications compared with anti-K10-negative RP patients.
The rate of anti-K10 positivity observed in this anti-RNP-positive cohort is similar to the percentage of MCTD patients in whom an aggressive vasculopathic phenotype developed, as reported by Szodoray and colleagues (29) . Because the in vitro experiments in this study were performed in the absence of interleukin-6 (IL-6) and neutrophils, future studies will be needed to determine whether the IL-6-associated apoptosis-inducing effects of scleroderma patient sera previously described by Barnes et al may also interact with the K10-mediated endothelial cell apoptosis pathway (30) . Future studies are warranted to determine whether endothelial cell expression levels of K10, Bim, and other components of this apoptotic pathway are linked to the risk of RP (and other forms of vasculopathy) in human cohorts, and whether modulation of the K10-induced apoptotic pathway may have diagnostic, prognostic, or therapeutic relevance in RP-associated autoimmune diseases.
Overall, our findings are the first to suggest a direct pathogenic link between humoral autoimmunity and RP as well as a new series of potential therapeutic approaches to be tested in RP that focus on the K10/Bim-mediated endothelial cell apoptosis pathway. The use of animal models of RP may expedite this discovery process and facilitate identification of therapeutic candidates for human trials. We have thus far used only animal models in short-term studies to assess the effects of autoantibodies on the induction of tissue ischemic injury. Longer-term application of these models could provide insight regarding the extent to which humorally induced endotheliopathy might be a sufficient stimulus to reconstitute additional elements of scleroderma pathology.
